Royal Australian College of General Practitioners (RACGP)·3 min read·medium

1 to hit Australian shelves within days

1 to hit Australian shelves within days
✦AI Summary

The TGA has approved Lilly's oral GLP-1 medication, orforglipron, for the treatment of obesity and type 2 diabetes in Australia. The drug will be available for prescription in the coming days, offering a non-peptide alternative to existing injectable treatments.

Why it matters

This marks a significant shift in obesity and diabetes management by providing an oral medication option that may improve patient adherence and accessibility.

✦Dive DeeperCreate a free account to unlock

The TGA has approved Foundayo for obesity and type 2 diabetes, with the pill ready for prescription 'in the coming days' and dispensed from Lilly's own platform and pharmacists.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthsciencebusiness
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in